The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has fostered change on several levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges posed by recombinant protein drugs, while administration of injectables has moved increasingly from practitioner offices and healthcare facilities to patient homes. This report examines the key therapeutic, product, market and regulatory factors for injectable drugs across ten major disease and therapeutic classes, providing essential insight and forecasts into the implications of this evolving landscape.
Analyzes and evaluates the shifting landscape for injectable drug delivery and assesses the market impact of new and emerging injectable drug products by therapeutic indication
Analyzes syringe and injector device designs, feature/functionality, product branding, competing technologies and market development issues
Provides detailed descriptions of key injectable drug therapeutic market segments, market demographics, and business strategies
Forecasts Injectable drug product demand by indication and therapy to 2018
Profiles leading injection device companies, their product development activities, business strategies, and corporate alliances and affiliations
Greystone Research Associates is pleased to announce the publication of a new market study. Injectable Drug Delivery to 2018: Drugs, Devices, Therapies, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.
Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.
Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.